MARKET

TCON

TCON

Tracon Pharmaceu
NASDAQ
1.500
-0.010
-0.66%
After Hours: 1.510 +0.01 +0.67% 18:06 11/28 EST
OPEN
1.480
PREV CLOSE
1.510
HIGH
1.530
LOW
1.470
VOLUME
32.97K
TURNOVER
0
52 WEEK HIGH
3.790
52 WEEK LOW
1.243
MARKET CAP
33.32M
P/E (TTM)
-1.0092
1D
5D
1M
3M
1Y
5Y
BRIEF-Tracon Pharmaceuticals Announces Dosing Of First Patient In Phase 1/2 Trial Of Yh001 In Combination With Envafolimab And Doxorubicin In Front Line Sarcoma
Reuters · 11/21 13:08
Tracon GAAP EPS of -$0.30 beats by $0.02
Seekingalpha · 11/15 07:48
BRIEF-TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results
Reuters · 11/14 21:51
TRACON Pharmaceuticals Q3 EPS $(0.30) Misses $(0.28) Estimate
Benzinga · 11/14 21:37
Notable earnings after Monday's close
Seekingalpha · 11/13 22:35
TRACON Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Benzinga · 11/07 13:36
BRIEF-TRACON To Report Q3 2022 Financial Results And Provide Corporate Update On November 14, 2022
Reuters · 10/31 12:09
TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer t...
GlobeNewswire · 10/31 12:00
More
About TCON
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.